HELP (Helus Pharma) Moat Score: 3/10 (As of Jul. 04, 2026)


HELP Helus Pharma Inc HELP
22 GF Score
Price $6.24
! 2 Warning Signs
View Full Analysis

What is Helus Pharma Moat Score?

Helus Pharma HELP -0.48% 22 Moat Score is 3 as of Jul. 04, 2026. GuruFocus rates HELP with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,399 Biotechnology companies, Helus Pharma ranks better than 75.48% on this metric.

Helus Pharma has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Helus Pharma has No Moat: Helus Pharma Inc has very weak competitive advantages. The company lacks significant intellectual property, regulatory barriers, or strong brand strength. Its market position does not provide a sustainable competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Helus Pharma might have No Moat - Very weak/transient advantages.

Helus Pharma  (NAS:HELP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Helus Pharma Moat Score Related Terms

HELP vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Helus Pharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helus Pharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helus Pharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Helus Pharma's Moat Score falls into.


HELP
22GF Score
Helus Pharma Inc HELP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Helus Pharma (HELP) has a Moat Score of 3 as of Jul. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Helus Pharma ranks #343 out of 1399 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Helus Pharma's Moat Score too high?
Helus Pharma's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Helus Pharma's value of 3 is 50% above this industry median. Based on the distribution chart, Helus Pharma ranks #343 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Helus Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helus Pharma ranks #343 out of 1399 companies for Moat Score. This places Helus Pharma in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Helus Pharma's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Helus Pharma's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helus Pharma's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Helus Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Helus Pharma (HELP), the current Moat Score is 3 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges R7E:GermanyHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
22GF Score

Get the complete analysis for HELP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.24
Price